Kotak said the near-term outlook for Gland Pharma is sluggish but the product pipeline and entry into new markets provide medium-term growth visibility.
Announcing the Q2 FY22 financial results, CEO Srinivas Sadu stated that Gland Pharma is on track to make four complex injectable filing during the current financial year